Profile data is unavailable for this security.
About the company
Sutro Biopharma, Inc. is a clinical-stage oncology company. The Company is engaged in developing site-specific and novel-format antibody drug conjugates (ADCs) enabled by its integrated cell-free protein synthesis platform, XpressCF, and its site-specific conjugation platform, XpressCF+. The Company’s advanced product candidate is STRO-002 (luveltamab tazevibulin, or luvelta), an ADC directed against folate receptor-alpha (FolRa), for patients with FolRa-expressing cancers, including ovarian cancer. In addition, it uses luvelta to treat pediatric patients with relapsed/refractory CBFA2T3-GLIS2 and acute myeloid leukemia. It also has two preclinical product candidates, STRO-003 and STRO-004. These product candidates are single homogeneous ADCs directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1), and tissue factor (TF), each of which is being developed for the treatment of solid tumors.
- Revenue in USD (TTM)154.07m
- Net income in USD-114.96m
- Incorporated2003
- Employees300.00
- LocationSutro Biopharma Inc111 Oyster Point Blvd.SOUTH SAN FRANCISCO 94080United StatesUSA
- Phone+1 (650) 392-8412
- Fax+1 (302) 655-5049
- Websitehttps://www.sutrobio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tenaya Therapeutics Inc | 0.00 | -124.58m | 330.56m | 140.00 | -- | 2.09 | -- | -- | -1.65 | -1.65 | 0.00 | 2.01 | 0.00 | -- | -- | 0.00 | -57.91 | -- | -63.59 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -0.3388 | -- | -- | -- |
| Cerus Corp | 191.72m | -31.56m | 330.95m | 288.00 | -- | 6.70 | -- | 1.73 | -0.1742 | -0.1742 | 1.06 | 0.2671 | 0.9623 | 1.92 | 8.03 | 665,680.60 | -15.91 | -25.99 | -24.20 | -40.62 | 61.73 | 61.90 | -16.53 | -35.81 | 1.72 | -2.16 | 0.6287 | -- | -0.8061 | 19.69 | 12.37 | -- | 32.07 | -- |
| Xeris Biopharma Holdings Inc | 171.36m | -64.40m | 334.32m | 377.00 | -- | -- | -- | 1.95 | -0.4648 | -0.4648 | 1.24 | -0.0619 | 0.5209 | 0.838 | 5.02 | 454,525.20 | -19.58 | -43.60 | -25.58 | -56.57 | 82.90 | 78.23 | -37.58 | -143.08 | 1.81 | -2.04 | 1.04 | -- | 48.68 | 131.50 | 34.23 | -- | 8.43 | -- |
| Zura Bio Ltd | 0.00 | -60.18m | 334.34m | 14.00 | -- | 3.75 | -- | -- | -1.63 | -1.63 | 0.00 | 1.40 | 0.00 | -- | -- | 0.00 | -86.77 | -- | -127.21 | -- | -- | -- | -- | -- | -- | -- | 0.021 | -- | -- | -- | -2,050.99 | -- | -- | -- |
| Ventyx Biosciences Inc | 0.00 | -192.60m | 336.99m | 74.00 | -- | 1.10 | -- | -- | -3.24 | -3.24 | 0.00 | 4.35 | 0.00 | -- | -- | 0.00 | -53.41 | -- | -55.81 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -77.97 | -- | -- | -- |
| Nautilus Biotechnology Inc | 0.00 | -67.44m | 343.23m | 163.00 | -- | 1.38 | -- | -- | -0.5402 | -0.5402 | 0.00 | 1.99 | 0.00 | -- | -- | 0.00 | -21.26 | -- | -21.85 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -9.93 | -- | -- | -- |
| Anavex Life Sciences Corp | 0.00 | -40.59m | 343.64m | 40.00 | -- | 2.52 | -- | -- | -0.4962 | -0.4962 | 0.00 | 1.61 | 0.00 | -- | -- | 0.00 | -26.73 | -40.04 | -28.98 | -43.97 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 0.9857 | -- | -- | -- |
| C4 Therapeutics Inc | 20.04m | -126.07m | 344.03m | 145.00 | -- | 1.33 | -- | 17.17 | -2.37 | -2.37 | 0.3677 | 3.76 | 0.0504 | -- | 2.84 | 138,179.30 | -31.74 | -25.91 | -36.02 | -29.45 | -- | -- | -629.24 | -292.35 | -- | -- | 0.00 | -- | -33.25 | 1.40 | -3.37 | -- | -8.68 | -- |
| Sutro Biopharma Inc | 154.07m | -114.96m | 345.58m | 300.00 | -- | 2.69 | -- | 2.24 | -1.89 | -1.89 | 2.53 | 1.57 | 0.4047 | -- | 7.48 | 510,149.00 | -30.20 | -25.48 | -36.94 | -29.75 | -- | -- | -74.62 | -113.71 | -- | -- | 0.00 | -- | 126.84 | 31.96 | 10.41 | -- | 22.61 | -- |
| OraSure Technologies, Inc. | 304.64m | 22.85m | 349.83m | 638.00 | 15.56 | 0.8207 | 8.17 | 1.15 | 0.304 | 0.304 | 4.11 | 5.76 | 0.6573 | 2.77 | 4.31 | 477,493.70 | 4.93 | 0.7238 | 5.42 | 0.8212 | 45.26 | 46.94 | 7.50 | 1.13 | 10.49 | -- | 0.0017 | 0.00 | 4.64 | 17.41 | 413.17 | 82.20 | 10.18 | -- |
| Shattuck Labs Inc | 2.72m | -85.08m | 350.93m | 75.00 | -- | 2.72 | -- | 129.25 | -1.93 | -1.93 | 0.0608 | 2.71 | 0.0168 | -- | -- | 36,200.00 | -52.52 | -29.14 | -57.94 | -32.42 | -- | -- | -3,133.63 | -565.33 | -- | -- | 0.00 | -- | 154.14 | -40.62 | 14.37 | -- | -19.15 | -- |
| Tourmaline Bio Inc | 0.00 | -32.94m | 353.15m | 44.00 | -- | 0.9972 | -- | -- | -5.35 | -5.35 | 0.00 | 13.81 | 0.00 | -- | -- | 0.00 | -12.39 | -- | -12.75 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 42.99 | -- | -- | -- |
| Precigen Inc | 5.44m | -96.91m | 353.39m | 202.00 | -- | 3.61 | -- | 64.97 | -0.3896 | -0.3896 | 0.0219 | 0.3877 | 0.0289 | -- | 4.12 | 26,925.74 | -51.49 | -31.50 | -64.42 | -38.63 | -4.19 | 44.00 | -1,781.73 | -232.32 | -- | -- | 0.00 | -- | -76.87 | -47.16 | -20.22 | -- | -48.30 | -- |
| Amarin Corporation plc (ADR) | 277.46m | -52.61m | 355.40m | 275.00 | -- | 0.6508 | -- | 1.28 | -0.1288 | -0.1288 | 0.679 | 1.33 | 0.3363 | 0.4197 | 2.23 | 1,008,927.00 | -6.38 | -4.48 | -8.90 | -6.54 | 63.61 | 75.70 | -18.96 | -8.59 | 1.93 | -- | 0.00 | -- | -16.87 | 6.01 | 44.13 | -- | 55.83 | -- |
| Cibus Inc | 2.32m | -285.67m | 356.99m | 183.00 | -- | 1.09 | -- | 153.87 | -18.29 | -18.29 | 0.1522 | 13.24 | 0.0084 | -- | -- | 12,677.60 | -129.84 | -86.28 | -147.90 | -96.45 | -- | -- | -15,483.49 | -792.07 | -- | -3.17 | 0.0039 | -- | 1,057.33 | 50.41 | -1,484.44 | -- | 18.53 | -- |
Data as of May 31 2024. Currency figures normalised to Sutro Biopharma Inc's reporting currency: US Dollar USD
42.79%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Point72 Asset Management LPas of 04 Apr 2024 | 5.93m | 7.71% |
| Suvretta Capital Management LLCas of 31 Mar 2024 | 5.78m | 7.51% |
| Millennium Management LLCas of 31 Mar 2024 | 4.74m | 6.16% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 4.55m | 5.91% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 2.98m | 3.87% |
| Kynam Capital Management LPas of 31 Mar 2024 | 2.00m | 2.60% |
| Adage Capital Management LPas of 31 Mar 2024 | 2.00m | 2.60% |
| Baillie Gifford & Co.as of 31 Mar 2024 | 1.85m | 2.40% |
| Parkman Healthcare Partners LLCas of 31 Mar 2024 | 1.79m | 2.33% |
| Dimensional Fund Advisors LPas of 31 Mar 2024 | 1.31m | 1.70% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
